Anthony Rosenzweig, MD
Stanley and Judith Frankel Professor of Heart and Brain Health
Professor of Internal Medicine
Professor of Pharmacology and Center Director
MM Institute for Heart and Brain Health
[email protected]

Available to mentor

Anthony Rosenzweig, MD
Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • About

    Dr. Rosenzweig, MD graduated from Harvard College, where he majored in biochemistry and molecular biology. He received his medical degree from Harvard Medical School and completed his residency in internal medicine and fellowship in cardiovascular medicine at the Massachusetts General Hospital (MGH). Additional research training included a one-year predoctoral fellowship in neurosciences at the University of Pennsylvania and postdoctoral training in the laboratories of Drs. Jonathan and Christine Seidman, as well as Dr. Michael Gimbrone, all at Harvard Medical School.

    Dr. Rosenzweig is the inaugural Director of the Stanley and Judith Frankel Institute for Heart and Brain Health (Frankel IHBH) at the University of Michigan Medical Center. Previous leadership roles include having served as Chief of Cardiology, Co-Director of the Corrigan Minehan Heart Center and Director of Cardiovascular Research at MGH as well as the Paul Dudley White Professor of Medicine at Harvard Medical School (2015-2022). He also has served as the inaugural Director of the Program in Cardiovascular Gene Therapy at MGH, a Trustee of the Harvard Clinical Research Institute (an academic clinical research organization), an Executive Committee member of the Harvard Stem Cell Institute and its Cardiovascular Program Leader, as well as the Director of Cardiovascular Research and Associate Chief of Cardiology at the Beth Israel Deaconess Medical Center in Boston. Dr. Rosenzweig is also a member of the Leducq Foundation Scientific Advisory Committee and the American Heart Association Basic Sciences Council leadership.

    Links
    • Rosenzweig Lab
    Qualifications
    • Residency in Internal Medicine
      Massachusetts General Hospital, Boston
    • Fellowship in Cardiovascular Medicine
      Massachusetts General Hospital, Boston
    • Postdoctoral Research Fellowship
      Harvard Medical School, Genetics
    • Postdoctoral Research Fellowship
      Brigham and Women's Hospital, Vascular Biology
    • M.D.
      Harvard Medical School, Boston
    Center Memberships
    • Center Member
      Biointerfaces Institute
    • Center Member
      Samuel and Jean Frankel Cardiovascular Center
    Research Overview

    Dr. Rosenzweig’s research has focused on identifying novel mechanisms and therapeutic targets in heart failure, using the exercised heart to understand what keeps hearts healthy. Of particular interest is how dysregulation of common pathways, such as those involved in metabolism, cellular senescence, or inflammation, can drive disease in multiple organs, including the brain and heart, since targeting such pathways could have broad clinical benefits. Dr. Rosenzweig is deeply committed to realizing the translational potential of basic science discoveries. His work has led to multiple patent awards, licensed approaches to mutation detection, and new therapeutic strategies being investigated in clinical trials. He has led successful partnerships with industry, served on industry advisory panels, and co-founded a recently funded biotech start-up focused on small molecule therapies for Long QT Syndrome. Dr. Rosenzweig has been a principal investigator for multiple successful research consortia including an international Leducq Foundation Network of Research Excellence, multiple NIH U-awards, an AHA Strategically Focused Research Network Center, and multiple NIH T32 training grants. His research has been continuously funded by the NIH for over 30 years.

    Recent Publications See All Publications
    • Journal Article
      The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial.
      Cheang I, Yao W, Zhou Y, Zhu X, Ni G, Lu X, Liao S, Gao R, Zhou F, Shen J, Leung AYL, Jiang M, Kong H, Bai L, Mahemuti A, Yuan H, Dong Y-G, Wong C-K, Xu Q, Zhang G, Wu J, Lu Q, Zhang J, Cha C, Ren Q, Fu L, Wang B, Xu Y, Hu H, Dong J, Shang Z, Yu C, Li S, Yao C, Gao L, Zhang H, Rosenzweig A, Jia Z, Li X, QUEST Trial Committees and Investigators . Nat Med, 2024 Aug; 30 (8): 2295 - 2302. DOI:10.1038/s41591-024-03169-2
      PMID: 39095596
    • Journal Article
      Translating metabolic and cardiovascular research into effective treatments: What's next?
      Zierath JR, van der Velden J, Javaheri A, Rosenzweig A, Muoio DM, Mulvihill EE, Martino TA, Rasheed A, Chen X-W, Arany ZP. Cell, 2024 Jul 25; 187 (15): 3880 - 3884. DOI:10.1016/j.cell.2024.06.034
      PMID: 39059364
    • Journal Article
      Cardiac aging: from hallmarks to therapeutic opportunities.
      Hastings MH, Zhou Q, Wu C, Shabani P, Huang S, Yu X, Singh AP, Guseh JS, Li H, Lerchenmüller C, Rosenzweig A. Cardiovasc Res, 2024 Jun 26; DOI:10.1093/cvr/cvae124
      PMID: 38918884
    • Journal Article
      Effect of Stress-Related Neural Pathways on the Cardiovascular Benefit of Physical Activity.
      Zureigat H, Osborne MT, Abohashem S, Mezue K, Gharios C, Grewal S, Cardeiro A, Naddaf N, Civieri G, Abbasi T, Radfar A, Aldosoky W, Seligowski AV, Wasfy MM, Guseh JS, Churchill TW, Rosovsky RP, Fayad Z, Rosenzweig A, Baggish A, Pitman RK, Choi KW, Smoller J, Shin LM, Tawakol A. J Am Coll Cardiol, 2024 Apr 23; 83 (16): 1543 - 1553. DOI:10.1016/j.jacc.2024.02.029
      PMID: 38631773
    • Journal Article
      Intrinsic and Extrinsic Contributors to the Cardiac Benefits of Exercise.
      Hastings MH, Castro C, Freeman R, Abdul Kadir A, Lerchenmüller C, Li H, Rhee J, Roh JD, Roh K, Singh AP, Wu C, Xia P, Zhou Q, Xiao J, Rosenzweig A. JACC Basic Transl Sci, 2024 Apr; 9 (4): 535 - 552. DOI:10.1016/j.jacbts.2023.07.011
      PMID: 38680954
    • Preprint
      Cardiomyocyte PGC-1α enables physiological adaptations to endurance exercise through suppression of GDF15 and cardiac atrophy
      Khetarpal SA, Li H, Vitale T, Rhee J, Grauvogel L, Castro C, Mittenbühler MJ, Houstis NE, Vargas-Castillo A, Smythers AL, Liu J, Curtin C, Sprenger H-G, Blackmore KA, Kuznetsov A, Freeman R, Bogoslavski D, Ellinor PT, Asnani A, Dumesic PA, Puigserver P, Roh JD, Spiegelman BM, Rosenzweig A. bioRxiv, DOI:10.1101/2024.01.30.578093
    • Journal Article
      Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
      Liu H, Yerevanian A, Westerhoff M, Hastings MH, Guerra JRB, Zhao M, Svensson KJ, Cai B, Soukas AA, Rosenzweig A. Diabetes, 2024 Feb 1; 73 (2): 260 - 279. DOI:10.2337/db23-0357
      PMID: 37934943
    • Journal Article
      miR-222 inhibits pathological cardiac hypertrophy and heart failure.
      Liu X, Li H, Hastings MH, Xiao C, Damilano F, Platt C, Lerchenmüller C, Zhu H, Wei XP, Yeri A, Most P, Rosenzweig A. Cardiovasc Res, 2024 Mar 14; 120 (3): 262 - 272. DOI:10.1093/cvr/cvad184
      PMID: 38084908
    Featured News & Stories AI generated heart and brains
    Research News
    Frankel IHBH and M-BoCA Present: Innovative Multidisciplinary Research Pilot Award 2025
    The Frankel IHBH is partnering with M-BoCA for the FY 25 Multidisciplinary Pilot Award.
    green background connecting to teal skull with brain inside both just outlines made out of felt
    Health Lab
    Can preventing inflammation improve heart and brain health?
    Michigan Medicine research study aims to address inflammation’s role in diseases of the heart and brain.
    Anthony Rosenzweig, M.D.
    Research News
    Medical School establishes Frankel IHBH; Anthony Rosenzweig, MD, is inaugural director.
    The mission for the institute is to become the world’s premier research institute discovering the root causes of heart and brain disease, determining how these organs communicate with each other, and developing the treatments of tomorrow.